Dual GLP-1/GLP-2 Agonist Injection Composition for Stability and Isotonicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Formulating stable and isotonic pharmaceutical compositions for GLP-1/GLP-2 dual agonists is challenging due to chemical instability, self-association, and osmotic imbalances, which can lead to degradation and discomfort during administration.
Innovation Solution
A chemically stable parenteral pharmaceutical composition comprising GLP-1/GLP-2 dual agonists with specific buffer and tonicity agent combinations, including phosphate buffer and mannitol or sodium chloride, maintains isotonicity and enhances chemical stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If peptides are formulated for parenteral administration, then they can be delivered systemically, but they suffer from chemical instability through deamidation and oxidation
Solution Approach 1:
The patent optimizes formulation parameters including pH (adjusted to 6.0-8.0 using phosphate buffer), ionic strength, and temperature to minimize deamidation and oxidation rates. Specific concentrations of phosphate buffer (5-50 mM) and tonicity agents (1-360 mM) are established to create optimal chemical stability conditions while maintaining systemic deliverability
Solution Approach 2:
Phosphate buffer and tonicity agents serve as intermediary substances that protect the peptide from chemical degradation. The buffer system controls pH to prevent acid-catalyzed deamidation, while tonicity agents like mannitol or sodium chloride create an isotonic environment that reduces osmotic stress and stabilizes the peptide structure during systemic circulation
2Ease of operation
If tonicity agents are added to achieve isotonicity, then patient comfort is improved, but peptide stability may be affected by additional excipients
Solution Approach 1:
The patent establishes specific concentration ranges for tonicity agents (1-360 mM) to achieve isotonicity (0.9% NaCl equivalence) while maintaining peptide stability. The formulation specifies that tonicity agents should be added to reach an osmolality of 280-320 mOsm/kg, which balances patient comfort with chemical stability by preventing osmotic shock and minimizing excipient-peptide interactions
Solution Approach 2:
The patent employs conventional, well-characterized tonicity agents like mannitol and sodium chloride that are inexpensive, physiologically compatible, and have established safety profiles. These excipients are used at controlled concentrations to provide immediate isotonicity without requiring complex stabilization systems, thereby maintaining peptide stability through simple, reliable formulation approaches
3Productivity
If peptide concentration is increased to reduce dosage volume, then administration efficiency is improved, but self-association and precipitation risks increase
Solution Approach 1:
The patent optimizes peptide concentration within specific ranges (0.1-100 mg/mL) and adjusts formulation parameters including phosphate buffer concentration (5-50 mM) and tonicity agent levels (1-360 mM) to maintain solubility and prevent self-association. The formulation creates an isotonic environment that reduces peptide-peptide interactions, allowing higher concentrations to be formulated without precipitation while improving administration efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves high chemical stability and isotonicity, ensuring safety and comfort during administration by minimizing degradation and osmotic shock.
Implementation Method 1
about 5 mM to about 50 mM of phosphate buffer component
Implementation Method 2
about 1-360 mM of one or more tonicity agent, preferably about 150-250 mM of one or more tonicity agent, wherein said one or more tonicity agent is an ionic or non-ionic tonicity agent
Data Source
AI summary
The present invention relates to pharmaceutical compositions suitable for parenteral administration in human subjects. In particular, the present invention relates to isotonic pharmaceutical compositions for parenteral administration.